Activest Wealth Management Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Activest Wealth Management reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 61.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,324 shares of the company’s stock after selling 2,100 shares during the period. Activest Wealth Management’s holdings in Moderna were worth $88,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MRNA. Intrinsic Value Partners LLC increased its holdings in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after acquiring an additional 24,505 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares during the period. Vontobel Holding Ltd. increased its position in shares of Moderna by 148.2% in the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after acquiring an additional 69,313 shares during the period. Profund Advisors LLC lifted its position in Moderna by 20.9% during the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after acquiring an additional 9,719 shares during the period. Finally, Principal Financial Group Inc. grew its stake in Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock valued at $25,359,000 after purchasing an additional 15,218 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Down 0.6 %

Shares of NASDAQ MRNA traded down $0.24 during trading on Thursday, hitting $36.70. 925,775 shares of the company were exchanged, compared to its average volume of 4,765,115. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47. The firm has a market capitalization of $14.12 billion, a PE ratio of -6.35 and a beta of 1.69. The company has a fifty day moving average price of $56.13 and a 200-day moving average price of $95.05. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.39) EPS. As a group, equities research analysts expect that Moderna, Inc. will post -9.44 EPS for the current year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 2,930 shares of company stock valued at $217,170 over the last 90 days. 15.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MRNA. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and reduced their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Berenberg Bank initiated coverage on Moderna in a research report on Tuesday. They set a “hold” rating and a $42.00 price target for the company. Finally, Piper Sandler restated an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research report on Monday. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $84.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.